Trimetazidine as an additional treatment – patient with ischemic heart disease and type 2 diabetes mellitus Case report
Article Sidebar
Published:
Dec 31, 2012
Main Article Content
Abstract
None
Article Details
How to Cite
Cacko, A. (2012). Trimetazidine as an additional treatment – patient with ischemic heart disease and type 2 diabetes mellitus. Medycyna Faktow (J EBM), 5(4(17), 53-56. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2442
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ochotny R.: Cytoprotekcja w leczeniu choroby wieńcowej. Znaczenie leków o modyfikowanym uwalnianiu. Folia Cardiol. 2003; 10(1): 1-8.
2. Kantor P.F., Lucien A., Kozak R. et al.: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000 Mar 17; 86(5): 580-8.
3. Charakterystyka produktu leczniczego. Centrum Informacji o Leku.
4. Fox K., Garcia M.A., Ardissino D. et al.: Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006 Jun; 27(11): 1341-81. Epub 2006 May 30.
5. Szwed H., Sadowski Z., Elikowski W. et al.: Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart J. 2001 Dec; 22(24): 2267-74.
6. Sellier P., Broustet J.P.: Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am. J. Cardiovasc. Drugs 2003; 3(5): 361-9.
7. Iyengar S.S., Rosano G.M.: Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: a preliminary study (METRO). Am. J. Cardiovasc. Drugs 2009; 9(5): 293-7.
2. Kantor P.F., Lucien A., Kozak R. et al.: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000 Mar 17; 86(5): 580-8.
3. Charakterystyka produktu leczniczego. Centrum Informacji o Leku.
4. Fox K., Garcia M.A., Ardissino D. et al.: Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006 Jun; 27(11): 1341-81. Epub 2006 May 30.
5. Szwed H., Sadowski Z., Elikowski W. et al.: Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart J. 2001 Dec; 22(24): 2267-74.
6. Sellier P., Broustet J.P.: Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am. J. Cardiovasc. Drugs 2003; 3(5): 361-9.
7. Iyengar S.S., Rosano G.M.: Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: a preliminary study (METRO). Am. J. Cardiovasc. Drugs 2009; 9(5): 293-7.